246 EUR-1008 (a new pancraetic enzyme product, PEP) was shown to be safe and effective in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI)

Efficacy and safety of Creon® 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis

“…The use of CNA to measure protein absorption is not as well characterised, although increases in CNA have been observed with pancreatic enzyme supplements in previous studies [21,22]. The significant treatment-associated differences in the CNA in the current study suggest that Creon was effective in improving protein digestion and absorption.…”